Literature DB >> 26891804

Genomic profiling of the genes on chromosome 3p in sporadic clear cell renal cell carcinoma.

Yoshikazu Togo1, Yoshie Yoshikawa2, Toru Suzuki1, Yoshiro Nakano2, Akihiro Kanematsu1, Masataka Zozumi3, Michio Nojima1, Seiichi Hirota3, Shingo Yamamoto1, Tomoko Hashimoto-Tamaoki2.   

Abstract

Somatic mutations of the BRCA1 associated protein-1 (BAP1) gene, which maps to 3p21, have been found in several tumors including malignant mesothelioma, uveal melanoma, and renal cell carcinoma (RCC). The role of BAP1 inactivation in tumor development remains unclear. It has been reported that Vhl knock-out mice did not develop RCC, but Vhl knock-out mice with single allele loss of Bap1 in nephron progenitor cells developed RCC, indicating that Bap1 inactivation may be essential in murine renal tumorigenesis. To clarify the role of BAP1 in human RCC development, we performed mutation analyses, including copy number detection of BAP1 and assessment of allelic imbalance using microsatellite polymorphisms on 3p, in 45 RCC samples derived from 45 patients without VHL or BAP1 germline mutation. Additionally, we analyzed the sequences of the VHL, PBRM1, and SETD2 genes, and examined promoter methylation of VHL. Using immunostaining, we also checked for expression of BAP1 protein, which is normally located in the nuclei. None of the RCCs had biallelic deletion of BAP1, but five (11.1%) showed a biallelic mutation (four with a sequence-level mutation with monoallelic loss and one with a biallelic sequence-level mutation); these cells were negative for nuclear BAP1 staining. These patients had worse recurrence-free survival than the patients without a biallelic mutation (p=0.046). However, there were no significant differences in worse outcome by multivariate analysis combined with age, T stage, histological subtype, infiltration and vascular invasion. In 35 RCCs (77.8%), monoallelic loss of BAP1 was accompanied by VHL biallelic mutation or VHL promoter hypermethylation. In five RCCs (11.1%), we detected 3p loss-of-heterozygosity, but the copy number of BAP1 was normal. Surprisingly, nuclear staining of BAP1 was negative in 10 out of 31 tumors (32.3%) with hemizygous normal BAP1, suggesting that haploinsufficiency may relate to RCC development.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26891804     DOI: 10.3892/ijo.2016.3395

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  9 in total

1.  SETD2 Haploinsufficiency for Microtubule Methylation Is an Early Driver of Genomic Instability in Renal Cell Carcinoma.

Authors:  Yun-Chen Chiang; In-Young Park; Esteban A Terzo; Durga Nand Tripathi; Frank M Mason; Catherine C Fahey; Menuka Karki; Charles B Shuster; Bo-Hwa Sohn; Pratim Chowdhury; Reid T Powell; Ryoma Ohi; Yihsuan S Tsai; Aguirre A de Cubas; Abid Khan; Ian J Davis; Brian D Strahl; Joel S Parker; Ruhee Dere; Cheryl L Walker; W Kimryn Rathmell
Journal:  Cancer Res       Date:  2018-05-03       Impact factor: 12.701

Review 2.  Renal Cell Carcinoma: Molecular Aspects.

Authors:  Aman Kumar; Niti Kumari; Vinny Gupta; Rajendra Prasad
Journal:  Indian J Clin Biochem       Date:  2017-11-13

3.  Clinical and molecular characteristics of unicentric mediastinal Castleman disease.

Authors:  Antoine Legras; Anne Tallet; Audrey Didelot; Aurélie Cazes; Claire Danel; Angela Hin; Raphaël Borie; Bruno Crestani; Yves Castier; Patrick Bagan; Françoise Le Pimpec-Barthes; Marc Riquet; Hélène Blons; Pierre Mordant
Journal:  J Thorac Dis       Date:  2018-04       Impact factor: 2.895

4.  Malignant Mesothelioma, BAP1 Immunohistochemistry, and VEGFA: Does BAP1 Have Potential for Early Diagnosis and Assessment of Prognosis?

Authors:  Emily Pulford; Kalyani Huilgol; David Moffat; Douglas W Henderson; Sonja Klebe
Journal:  Dis Markers       Date:  2017-09-11       Impact factor: 3.434

5.  Increased expression of RBMS3 predicts a favorable prognosis in human gallbladder carcinoma.

Authors:  Youliang Wu; Delong Meng; Yexiang You; Ruochuan Sun; Qiang Yan; Junjun Bao; Yanjun Sun; Dapeng Yun; Yongxiang Li; Dengqun Sun
Journal:  Oncol Rep       Date:  2020-04-23       Impact factor: 3.906

6.  Loss of BAP1 expression is associated with genetic mutation and can predict outcomes in gallbladder cancer.

Authors:  Takashi Hirosawa; Masaharu Ishida; Kentaro Ishii; Keigo Kanehara; Katsuyoshi Kudo; Shinobu Ohnuma; Takashi Kamei; Fuyuhiko Motoi; Takeshi Naitoh; Florin M Selaru; Michiaki Unno
Journal:  PLoS One       Date:  2018-11-05       Impact factor: 3.240

7.  Genetic alteration of histone lysine methyltransferases and their significance in renal cell carcinoma.

Authors:  Libin Yan; Yangjun Zhang; Beichen Ding; Hui Zhou; Weimin Yao; Hua Xu
Journal:  PeerJ       Date:  2019-02-06       Impact factor: 2.984

8.  Risk prediction for metastasis of clear cell renal cell carcinoma using digital multiplex ligation-dependent probe amplification.

Authors:  Yoshie Yoshikawa; Yusuke Yamada; Mitsuru Emi; Lilit Atanesyan; Jan Smout; Karel de Groot; Suvi Savola; Yukako Nakanishi-Shinkai; Akihiro Kanematsu; Michio Nojima; Masaki Ohmuraya; Tomoko Hashimoto-Tamaoki; Shingo Yamamoto
Journal:  Cancer Sci       Date:  2021-11-03       Impact factor: 6.716

Review 9.  Biological Mechanisms and Clinical Significance of BAP1 Mutations in Human Cancer.

Authors:  Michele Carbone; J William Harbour; James Brugarolas; Angela Bononi; Ian Pagano; Anwesha Dey; Thomas Krausz; Harvey I Pass; Haining Yang; Giovanni Gaudino
Journal:  Cancer Discov       Date:  2020-07-20       Impact factor: 38.272

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.